The U.S. Food and Drug Administration approved Benlysta, a drug designed to treat lupus erythematosus. Not only Benlysta the first new drug for lupus in more than 50 years to reach the market, but is the first drug derived from the study of genes. It 'been a long, though. Human Genome Benlysta partner, GlaxoSmithKline Plc, first invested in U.S. biotech company in 1993.
Develop Benlysta has done for many years and is a product of a joint effort by Human Genome Sciences, Inc. and GlaxoSmithKline. So far, Benlysta is the first drug approved by FDA, which has developed 20-year-old company Human Genome Sciences.
HGS has discovered a natural protein, B-lymphocyte stimulator, or BLyS, in 1996 and published a preliminary description of the activities in a magazine, Science, July 1999. After this discovery, HGS has initiated a program to develop human monoclonal antibodies capable of recognizing and preventing the biological activity of BLyS. BENLYSTA is a human monoclonal antibody generated by HGS with Cambridge Antibody Technology.
No comments:
Post a Comment